imnunogenicity < impact < impacts

Facettes : Author.f AffPays.f AffOrg.f AffRegion.f AffVille.f

List of bibliographic references

Number of relevant bibliographic references: 50.
[0-20] [0 - 20][0 - 50][20-40]

Ident.	Authors (with country if any)	Title
000050 (2011)	Masaaki Hiura [Japon] ; Shintaro Abe ; Akinari Tabaru ; Shohei Shimajiri ; Kentaro Hanami [Japon] ; Kazuyoshi Saito [Japon] ; Yoshiya Tanaka [Japon] ; Masaru Harada	Case of severe liver damage after the induction of tocilizumab therapy for rheumatoid vasculitis
000068 (2012)	Yee Chiu [Royaume-Uni] ; Andrew J. K. Ostor [Royaume-Uni] ; Anthony Hammond [Royaume-Uni] ; Katharina Sokoll [Royaume-Uni] ; Marina Anderson [Royaume-Uni] ; Maya Buch [Royaume-Uni] ; Michael R. Ehrenstein [Royaume-Uni] ; Patrick Gordon [Royaume-Uni] ; Sophia Steer [Royaume-Uni] ; Ian N. Bruce [Royaume-Uni]	Access to the next wave of biologic therapies (Abatacept and Tocilizumab) for the treatment of rheumatoid arthritis in England and Wales
000133 (2009)	Shin-Ya Kawashiri [Japon] ; Atsushi Kawakami [Japon] ; Satoshi Yamasaki [Japon] ; Takahiro Imazato [Japon] ; Naoki Iwamoto [Japon] ; Keita Fujikawa [Japon] ; Toshiyuki Aramaki [Japon] ; Mami Tamai [Japon] ; Hideki Nakamura [Japon] ; Hiroaki Ida [Japon] ; Tomoki Origuchi [Japon] ; Yukitaka Ueki [Japon] ; Katsumi Eguchi [Japon]	Effects of the anti-interleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis
000233 (2010)	Hiroshi Kato [États-Unis] ; David A. Fox [États-Unis]	Are Th17 Cells an Appropriate New Target in the Treatment of Rheumatoid Arthritis?
000296 (2012)	Adel Alawadhi [Koweït] ; Khaldoon Alawneh [Jordanie] ; Zeyad Ahmed Alzahrani [Arabie saoudite]	The effect of neutralizing antibodies on the sustainable efficacy of biologic therapies: what’s in it for African and Middle Eastern rheumatologists
000421 (2013)	P. N. Morcos [États-Unis] ; S. A. Moreira [États-Unis] ; B. J. Brennan [États-Unis] ; S. Blotner [États-Unis] ; N. S. Shulman [États-Unis] ; P. F. Smith [États-Unis]	Influence of chronic hepatitis C infection on cytochrome P450 3a4 activity using midazolam as an in vivo probe substrate
000511 (2011)	Stefan Kleinert [Allemagne] ; Hans-Peter Tony [Allemagne] ; Andreas Krause [Allemagne] ; Martin Feuchtenberger [Allemagne] ; Siegfried Wassenberg [Allemagne] ; Constanze Richter [Allemagne] ; Ekkehard Röther [Allemagne] ; Wolfgang Spieler [Allemagne] ; Holger Gnann [Allemagne] ; Bianca M. Wittig [Allemagne]	Impact of patient and disease characteristics on therapeutic success during adalimumab treatment of patients with rheumatoid arthritis: data from a German noninterventional observational study
000519 (2010)	Steven Simoens [Belgique] ; Thomas De Rijdt [Belgique] ; Paul Declerck	Monoclonal antibodies: indications, budget impact and use
000535 (2013)	Oliver Foot ; Anshuman Malaviya	Treatment of rheumatoid arthritis: current and future
000561 (2013)	N. Takahashi [Japon] ; T. Kojima [Japon] ; K. Funahashi [Japon] ; D. Kato [Japon] ; H. Matsubara [Japon] ; Y. Hattori [Japon] ; N. Ishiguro [Japon]	AB0563 Impact of the history and the type of previous biologic treatment on abatacept efficacy in rheumatoid arthritis patients
000730 (2016)	Henning Steinhagen [Allemagne]	Igniting Small‐Molecule Drug Discovery
000736 (2013)	A. Ruyssen-Witrand [France] ; P.-A. Gourraud [États-Unis] ; D. Nigon [France] ; C. Lukas [France] ; C. Miceli-Richard ; B. Jamard ; A. Cantagrel ; A. Cambon-Thomsen [France] ; P. Dieudé [France] ; A. Constantin [France]	OP0050 Evolution of the alternative classification of HLA-DRB1 alleles in rheumatoid arthritis: Impact on the production of the anti-citrullinated protein antibodies and structural progression, data from the ESPOIR cohort
000757 (2013)	C. B. Jacklin ; A. Bosworth [Royaume-Uni]	OP0158-PARE Survey of the Impact of RA on Family Relationships
000770 (2013)	E. Filatova ; S. Erdes ; V. Alekseev [Russie]	AB0309 The impact of modern antirheumatic therapy on the neuropathic component of pain in patients with ra
000793 (2011)	Sheila L. Arvikar [États-Unis] ; Mark C. Fisher [États-Unis]	Inflammatory bowel disease associated arthropathy
000873 (2012)	Eugenia K. Page [États-Unis] ; Wasim A. Dar [États-Unis] ; Stuart J. Knechtle [États-Unis]	Biologics in organ transplantation
000911 (2016)	Af Poirier [États-Unis] ; Wr Murphy [États-Unis]	The Impact of Breakthrough Therapy Designation on Development Strategies and Timelines for Nononcology Drugs and Vaccines
000956 (2009)	Larry W. Moreland [États-Unis]	Cytokines as Targets for Anti‐inflammatory Agents
000991 (2013)	G. A. Karpouzas ; J. Malpeso [États-Unis] ; T.-Y. Choi [États-Unis] ; S. Munoz ; M. Budoff [États-Unis]	THU0057 Differential impact of traditional cardiac risk factors on coronary plaque prevalence in coronary artery disease (CAD)-naïve subjects with rheumatoid arthritis compared to controls
000A53 (2010)	Hiroto Yoshida [Japon] ; Misato Hashizume [Japon] ; Masahiko Mihara [Japon]	IL-6 blockade preferentially inhibits Th17 differentiation in collagen-induced arthritis
000B66 (2014)	W. H. Boehncke [Suisse] ; A. Qureshi [États-Unis] ; J. F. Merola [États-Unis] ; D. Thaçi [Allemagne] ; G. G. Krueger [États-Unis] ; J. Walsh [États-Unis] ; N. Kim [États-Unis] ; A. B. Gottlieb [États-Unis]	Diagnosing and treating psoriatic arthritis: an update

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Istex/Curation

HfdIndexSelect -h $EXPLOR_AREA/Data/Istex/Curation/AbsEn.i -k "impact" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Istex/Curation/AbsEn.i  \
                -Sk "impact" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Istex
   |étape=   Curation
   |type=    indexItem
   |index=    AbsEn.i
   |clé=    impact
}}

---

This area was generated with Dilib version V0.6.34. Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021